Calidi Biotherapeutics, Inc. Balance Sheet
CLDI|1 years of annual SEC 10-K data (FY2023-FY2023)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity. All figures from audited SEC 10-K filings.
Calidi Biotherapeutics, Inc. had $10M in total assets with negative shareholders' equity of $8M as of FY2023. Total debt stood at $2M as of FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.02 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| Current Assets | $4.3M |
| PP&E (Net) | $1.3M |
| Total Assets | $10.0M |
| Current Liabilities | $10.2M |
| Total Debt | $2.1M |
| Shareholders' Equity | -$8.2M |